DE · BNN.DE
BRAIN Biotech AG
- Sector
- Healthcare · Biotechnology
- Headquarters
- Zwingenberg 64673
- Website
- brain-biotech.com
Price · as of 2025-09-30
$2.76
Market cap 53.09M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $24.47 | +786.59% |
| Intrinsic Value(DCF) | $1.21 | -56.16% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $0.36 | -86.96% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | $0.00 | $0.00 | |||
| 2014 | $0.00 | $0.00 | |||
| 2015 | $0.00 | $0.00 | |||
| 2016 | $15.36 | $26.42 | $9.80 | $0.00 | $0.00 |
| 2017 | $21.04 | $45.19 | $0.99 | $0.00 | $0.00 |
| 2018 | $12.78 | $30.84 | $0.45 | $0.00 | $0.00 |
| 2019 | $9.38 | $40.73 | $41.13 | $0.00 | $0.00 |
| 2020 | $8.22 | $23.60 | $0.70 | $0.00 | $0.00 |
| 2021 | $9.00 | $31.27 | $0.36 | $0.46 | $0.00 |
| 2022 | $6.56 | $46.23 | $0.11 | $0.00 | $0.00 |
| 2023 | $3.45 | $29.24 | $1.86 | $0.00 | $0.00 |
| 2024 | $3.83 | $26.38 | $0.00 | $0.00 | $0.00 |
| 2025 | $3.03 | $24.47 | $0.00 | $0.00 | $0.36 |
AI valuation
Our deep-learning model estimates BRAIN Biotech AG's (BNN.DE) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $24.47
- Current price
- $2.76
- AI upside
- +786.59%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1.21
-56.16% upside
Graham-Dodd
—
— upside
Graham Formula
$0.36
-86.96% upside
About BRAIN Biotech AG
BRAIN Biotech AG researches, develops, produces, and markets enzymes, biocatalysts, microorganisms, and bioactive natural substances for chemical industries in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates in two segments, BioScience and BioIndustrial. It identifies and develops bioactive natural compounds, including sugar substitutes and taste modulators, and nature-based active ingredients for product development in the food, animal feed, skin care, cosmetics, and chemical industries. The company also identifies and develops optimized enzymes and biocatalysts for the production of food and beverages, and wound care preparations or lubricants, as well as for starch processing of bioethanol production; and microorganisms as the functional biomass for optimized industrial production processes, recycling of greenhouse gas CO2 as an industrial raw material, and extraction of precious and rare earth metals. It has strategic partnerships with AnalytiCon Discovery GmbH and Roquette to develop natural sweeteners and sweet taste enhancers. The company was formerly known as B.R.A.I.N. Biotechnology Research and Information Network AG and changed its name to BRAIN Biotech AG in April 2021. BRAIN Biotech AG was founded in 1993 and is headquartered in Zwingenberg, Germany.
- CEO
- Adriaan Moelker
- Employees
- 296
- Beta
- 0.60
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1.21 ÷ $2.76) − 1 = -56.16% (DCF, example).